A Director at Biospecifics Technologies Corp (BSTC) is Buying Shares

Yesterday, a Director at Biospecifics Technologies Corp (NASDAQ: BSTC), Michael Schamroth, bought shares of BSTC for $204K.

This recent transaction increases Michael Schamroth’s holding in the company by 21.74% to a total of $3.62 million. Following Michael Schamroth’s last BSTC Buy transaction on January 27, 2016, the stock climbed by 5.4%.

See today’s analyst top recommended stocks >>

BSTC’s market cap is $310.3M and the company has a P/E ratio of 26.44. Currently, Biospecifics Technologies Corp has an average volume of 9,403.

Starting in November 2013, BSTC received 23 Buy ratings in a row.

Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

BioSpecifics Technologies Corp. engages in the development of an injectable collagenase for multiple indications. Its product includes XIAFLEX, is an injectable collagenase enzyme, which is used for the treatment of Dupuytren’s contracture in adults with a palpable cord in the palm. The company was founded in 1990 and is headquartered in Lynbrook, NY.